Long-term efficacy of upstream therapy using angiotensin-converting enzyme inhibitors and statins in combination with antiarrhythmic agents for the treatment of paroxysmal atrial fibrillation

International Heart Journal

Volumn 50, Issue 4, 2009, Pages 465-476

  Komatsu, Takashi ^a   Tachibana, Hideaki ^a   Sato, Yoshihiro ^a   Ozawa, Mahito ^a   Kunugida, Fusanori ^a   Orii, Makoto ^a   Nakamura, Motoyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiarrhythmic drug; Atrial fibrillation; Enalapril; Pravastatin

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; APRINDINE; BEPRIDIL; ENALAPRIL; PRAVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; JAPANESE; LOADING DRUG DOSE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RECURRENT DISEASE; RHABDOMYOLYSIS; SIDE EFFECT; SINUS RHYTHM; COHORT ANALYSIS; DRUG ADMINISTRATION; DRUG COMBINATION; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 70349262652     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.50.465     Document Type: Article

References (40)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469-73.
2. Braunwald E. Shattuck Lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities, N Engl J Med 1997; 337: 1360-9.
3. Tanizaki Y, Kiyohara Y, Kato I, et al. Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayayama. Study. Stroke 2000; 31: 2616-22.
4. Ohsawa M, Okayama A, Okamura T, et al. Mortality risk attributable to atrial fibrillation in middle-aged and elderly people in the Japanese general population: nineteen-year follow-up in NIPPON DATA 80. Circ J 2007; 71: 814-9.
5. Komatsu T, Nakamura S, Suzuki O, et al. Long-term prognosis of patients with paroxysmal atrial fibrillation depends on their response to antiarrhythmic therapy. Circ J 2004; 68: 729-33.
6. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and, the Heart Rhythm Society. Circulation 2006; 114: e257-354.
7. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Eng J Med 2001; 344: 1411-20.
8. Sopher SM, Camm AJ. Atrial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol 1996; 77: 24A-37A. (Review)
9. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
10. Investigating Committee of Guideline for Diagnosis and Treatment of Hyperlipidemias: Guidelines for diagnosis and treatment of hyperlipidemia in adults. J Jpn Atheroscler Soc 1997; 25: 1-34.
11. Komatsu T, Sato Y, Tachibana H, Nakamura M, Horiuchi D, Okumura K. Randomized crossover study of the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation: influence of the duration of arrythmia before therapy. Circ J 2006; 70: 667-72.
12. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-204.
13. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation 1996; 94: 2968-74.
14. + current in chronic dog model of atrial fibrillation. Circ Res 1997; 81: 1045-52.
15. Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988;62:395-410.
16. Willems R, Sipido KR, Holemans P, Ector H, Van de Werf F, Heidbüchel H. Different patterns of angiotensin II and atrial natriuretic peptide secretion in a sheep model of atrial fibrillation. J Cardiovasc Electrophsiol 2001; 12: 1387-92.
17. Goette A, Staack T, Röcken C, et al. Increased expression of extracellular signal-regulated kinase angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-77.
18. Bode F, Katchman A, Woosley RL, Franz MR. Gadolinium decreases stretch-induced vulnerability to atrial fibrillation. Circulation 2000; 101: 2200-5.
19. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in isolated Langendorff-perfused rabbit heart. Circulation 1997; 96: 1686-95.
20. Gottlieb SS, Diekstein K, Fleck E, et al. Hemodynamic and neuronormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88: 1602-9.
21. Lonn EM, Yusuf S, Jha P. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056-69. (Review)
22. + current via the AT1 receptor in guinea pig atrial myocytes. Circulation 2006; 113: 1278-86.
23. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res 2003; 60: 315-25.
24. Fliser D, Buchholz K, Haller H, et al. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-7.
25. Komatsu T, Ozawa M, Tachibana H, et al. Combination therapy with amiodarone and enalapril in patients with paroxysmal atrial fibrillation prevents the development of structural atrial remodeling. Int Heart J 2008; 49: 435-47.
26. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-6.
27. Basso C, Corrado D, Rossi L, Thiene G. Ventricular preexcitation in children and young adults: atrial myocarditis as a possible trigger of sudden death. Circulation 2001; 103: 269-75.
28. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-4.
29. Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model. Insights into the mechanism of its maintenance. Circulation 1997; 95: 511-21.
30. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-91.
31. Dudley SC Jr, Hoch NE, MaCann LA, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of NADPH and xanthine oxidases. Circulation 2005; 112: 1266-73.
32. Kim YM, Guzik TJ, Zhang YH, et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005; 97: 629-36.
33. Shiroshita-Takeshita A, Brundel BJ, Burstein B, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007; 74: 75-84.
34. Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP, AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 2003; 42: 81-7.
35. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-83.
36. Siu CW, Lau CP, Tse HE Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-5.
37. Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006; 97: 1490-3.
38. Komatsu T, Tachibana H, Sato Y, et al. Long-term efficacy of combination therapy with antiarrhythmic agents and pravastatin in patients with paroxysmal atrial fibrillation. J Arrhythmia 2007; 23: 124-30.
39. Page RL, Wilkinson WE, Clair WK, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224-7.
40. Fukuda Y, Akashi M, Noma S, et al. Asymptomatic recurrence of atrial fibrillation - Cardiophone-guided management. Circ J 2003; 67 (Suppl I): 310.